Media Thread, page-5347

Had a closer re-watch of Leslie's interview with Proactive Investors yesterday. Lots of announcements and catalysts to come during 2022.

Q. Imugene receiving ethics approval for your Phase 2 HER-VAXX trial. Clearly a milestone, tell us a bit more about it.
A. It's a Phase 2 study in combination with Pembrolizumab, better known as KEYTRUDA. This is one of many combinations HER-VAXX is going into and as a company we have lots of combinations happening, but we're just delighted that the site opened ahead of schedule and that we can actually obtain Pembrolizumab off the shelf expeditiously, and we can start dosing patients.

Q. When can you start dosing patients?
A. We still have to go through several lines of committees but the fact that we can just buy the drug Pembrolizumab off the shelf really helps expedite it...I'm moving the team as fast as they can go.

Q. As you said this is one of a number of combinations studies, any updates on the others?
A. Delighted to announce here soon, Vaxinia, that's our parental CF33 virus going into the clinic. There's actually several patients being screened atm, so we've got, [that] (eg trial updates) coming very soon.

CHECKVacc is already in cohort 2 and CHECKVacc has the CF33 with PDL1-transgene, that first cohort of patients is producing some very interesting data and I can't wait to publish on that here soon.

We've got PD1-VAXX, the non-small lung study that will be combining with tenzentricatazamulab. Now, we already saw some complete responders, as well as some stable disease and PRs in the monotherapy dose escalation. I just am out of my skin excited about that combination, so [that's] (eg data announcement) coming very soon.

We have onCARlytics our CF33 that shuttles up the CD19 flags. Everyone knows we are in partnership with Cellularity and Eureka and that in-vivo/in-vitro data is soon to be published: they're just finishing up some more experiments.

Q. Well-cashed up also?A. That's right, we have well over $100 million in the bank.